Research Topics
Genomes and GenesSpecies | Karol L ThompsonSummaryAffiliation: Food and Drug Administration Country: USA Publications
| Collaborators
|
Detail Information
Publications
Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in ratsKarol L Thompson
Division of Drug Safety Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
Toxicol Lett 213:285-91. 2012..These data help define the potential context-of-use of serum di-22:6-BMP as a non-clinical biomarker of PLD...- Using population physiologically based pharmacokinetic modeling to determine optimal sampling times and to interpret biological exposure markers: The example of occupational exposure to styreneMarc André Verner
Institute of Environmental Medicine, Karolinska Institute, Solna 171 77, Sweden
Toxicol Lett 213:299-304. 2012..Biomonitoring of chemicals in the workplace provides an integrated characterization of exposure that accounts for uptake through multiple pathways and physiological parameters influencing the toxicokinetics... - Comparison of the diagnostic accuracy of di-22:6-bis(monoacylglycerol)phosphate and other urinary phospholipids for drug-induced phospholipidosis or tissue injury in the ratKarol L Thompson
Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Building 64, Room 2036, Silver Spring, MD 20993, USA
Int J Toxicol 31:14-24. 2012..The data provide evidence supporting the use of di-22:6-BMP as a urinary biomarker of PLD in rats... 
Characterization of the effect of sample quality on high density oligonucleotide microarray data using progressively degraded rat liver RNAKarol L Thompson
Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
BMC Biotechnol 7:57. 2007....- Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in ratsKarol L Thompson
Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
Cancer Chemother Pharmacol 66:303-14. 2010..To identify potential additional cardioprotective treatment strategies, we investigated early doxorubicin-induced changes in cardiac gene expression... - Comparison of the diagnostic performance of human whole genome microarrays using mixed-tissue RNA reference samplesKarol L Thompson
Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
Toxicol Lett 186:58-61. 2009.... - Use of a mixed tissue RNA design for performance assessments on multiple microarray formatsKarol L Thompson
Center for Drug Evaluation and Research, US FDA, Silver Spring, MD 20993, USA
Nucleic Acids Res 33:e187. 2005..The mixed tissue design produces a reagent with known gene expression changes within a complex sample and can serve as a paradigm for performance standards for microarrays that target other species... 
Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent componentsKarol L Thompson
Division of Applied Pharmacology Research, Office of Testing and Research, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland 20708, USA
Toxicol Sci 74:271-8. 2003..However, vehicle composition must be carefully selected because the outcome of this assay can be confounded by certain commonly used solvents...- Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromiumYuzhao Zhou
Center for Devices and Radiological Health, U S Food and Drug Administration, White Oak Life Sciences Laboratory, Silver Spring, MD 20993, USA
Toxicol Sci 101:159-70. 2008..Urinary Kim-1 and kidney Kim-1/Havcr1 expression appear to be sensitive and tissue-specific biomarkers that will improve detection of early acute kidney injury following exposure to nephrotoxic chemicals and drugs... - An adaptable method using human mixed tissue ratiometric controls for benchmarking performance on gene expression microarrays in clinical laboratoriesP Scott Pine
Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993 USA
BMC Biotechnol 11:38. 2011..To increase the clinical utility of microarrays, assay controls are needed that benchmark performance using metrics that are relevant to the analysis of genomic data generated with biological samples... - The utility of a rodent model in detecting pediatric drug-induced nephrotoxicityParvaneh Espandiari
Center for Drug Evaluation and Research, Silver Spring, Maryland 20993, USA
Toxicol Sci 99:637-48. 2007.... - Identification of platform-independent gene expression markers of cisplatin nephrotoxicityKarol L Thompson
Center for Drug Evaluation and Research, Division of Applied Pharmacology Research, U S Food and Drug Administration, 10903 New Hampshire Avenue, Life Sciences Building 64, Silver Spring, MD 20993, USA
Environ Health Perspect 112:488-94. 2004.... - Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitroKarol L Thompson
Division of Applied Pharmacology Research, Office of Testing and Research, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland 20708, USA
Toxicol Sci 74:260-70. 2003..Based on these criteria, amiloride, dipyridamole, and pyrimethamine were selected from 99 rodent noncarcinogens in a drug database for testing the specificity of the Tg.AC assay... - Sources of variation in baseline gene expression levels from toxicogenomics study control animals across multiple laboratoriesMichael J Boedigheimer
CDER, US FDA, Silver Spring, MD 20993, USA
BMC Genomics 9:285. 2008.... - Improvement in the reproducibility and accuracy of DNA microarray quantification by optimizing hybridization conditionsTao Han
Center for Functional Genomics, National Center for Toxicological Research, US FDA, Jefferson, AR 72079, USA
BMC Bioinformatics 7:S17. 2006..A successful microarray experiment, however, involves many steps: well-designed oligonucleotide probes, printing, RNA extraction and labeling, hybridization, and imaging. Optimization is essential to generate reliable microarray data... - Quality control of microarray assays for toxicogenomic and in vitro diagnostic applicationsKarol L Thompson
Division of Applied Pharmacology Research, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland, USA
Methods Mol Biol 460:45-68. 2008..Regulations and guidelines involved in the application of microarrays as a commercial in vitro diagnostic device are also described... - Evaluation of the Tg.AC transgenic mouse assay for testing the human carcinogenic potential of pharmaceuticals--practical pointers, mechanistic clues, and new questionsFrank D Sistare
Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland 20708, USA
Int J Toxicol 21:65-79. 2002..Data relating to mechanisms of chemical tumor induction in the Tg.AC model are reviewed, and questions have been formulated to encourage research to further guide appropriate future applications of this model... - Kidney injury biomarkers in hypertensive, diabetic, and nephropathy rat models treated with contrast mediaRodney L Rouse
1Division of Drug Safety Research, Office of Testing and Research, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland, USA
Toxicol Pathol 41:662-80. 2013..2m, Lcn-2, and BUN were the best predictors of histopathology defined kidney injury... - The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurementsLeming Shi
National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas 72079, USA
Nat Biotechnol 24:1151-61. 2006..This study provides a resource that represents an important first step toward establishing a framework for the use of microarrays in clinical and regulatory settings... - Identification of putative gene based markers of renal toxicityRupesh P Amin
National Institute of Environmental Health Sciences, National Institutes of Health/DHHS, Research Triangle Park, North Carolina, USA
Environ Health Perspect 112:465-79. 2004..We conclude that renal gene expression profiling coupled with analysis of classical end points affords promising opportunities to reveal potential new mechanistic markers of renal toxicity... - Analysis of variance components in gene expression dataJames J Chen
Division of Biometry and Risk Assessment, National Center for Toxicology Research, Food and Drug Administration, Jefferson, AR 72079, USA
Bioinformatics 20:1436-46. 2004..Finally, we describe the use of variance-component estimates to determine optimal numbers of animals, arrays per animal and sections per array in planning microarray experiments... - Normalization methods for analysis of microarray gene-expression dataYi-Ju Chen
Division of Biometry and Risk Assessment, National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas 72079, USA
J Biopharm Stat 13:57-74. 2003..The method that combines a subset approach (median or lowess fit) for location adjustment with a global lowess fit for intensity adjustment appears to perform well...